Bancroft JD, Kreamer B, Gourley GR (1998). «Gilbert syndrome accelerates development of neonatal jaundice». Journal of Pediatrics. 132 (4): 656–60. PMID9580766. doi:10.1016/S0022-3476(98)70356-7
Cappellini MD, Di Montemuros FM, Sampietro M, Tavazzi D, Fiorelli G (1999). «The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels». British Journal of Haematology. 104 (4): 928–9. PMID10192462. doi:10.1111/j.1365-2141.1999.1331a.x
Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J (2004). «Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype». Int J Clin Pharmacol Ther. 42 (2): 73–7. PMID15180166. doi:10.5414/cpp42073
Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW (2003). «Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians». Biochem Pharmacol. 65 (9): 1521–7. PMID12732365. doi:10.1016/S0006-2952(03)00074-1
Esteban A, Pérez-Mateo M (1999). «Heterogeneity of paracetamol metabolism in Gilbert's syndrome». European Journal of Drug Metabolism and Pharmacokinetics. 24 (1): 9–13. PMID10412886. doi:10.1007/BF03190005
Ladislav Novotnýc; Libor Vítek (2003). «Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies». Experimental Biology and Medicine. 228 (5): 568–571. PMID12709588. doi:10.1177/15353702-0322805-29
Vítek L; Jirsa M; Brodanová M; et al. (2002). «Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels». Atherosclerosis. 160 (2): 449–56. PMID11849670. doi:10.1016/S0021-9150(01)00601-3
Bancroft JD, Kreamer B, Gourley GR (1998). «Gilbert syndrome accelerates development of neonatal jaundice». Journal of Pediatrics. 132 (4): 656–60. PMID9580766. doi:10.1016/S0022-3476(98)70356-7
Cappellini MD, Di Montemuros FM, Sampietro M, Tavazzi D, Fiorelli G (1999). «The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels». British Journal of Haematology. 104 (4): 928–9. PMID10192462. doi:10.1111/j.1365-2141.1999.1331a.x
Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J (2004). «Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype». Int J Clin Pharmacol Ther. 42 (2): 73–7. PMID15180166. doi:10.5414/cpp42073
Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW (2003). «Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians». Biochem Pharmacol. 65 (9): 1521–7. PMID12732365. doi:10.1016/S0006-2952(03)00074-1
Esteban A, Pérez-Mateo M (1999). «Heterogeneity of paracetamol metabolism in Gilbert's syndrome». European Journal of Drug Metabolism and Pharmacokinetics. 24 (1): 9–13. PMID10412886. doi:10.1007/BF03190005
Ladislav Novotnýc; Libor Vítek (2003). «Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies». Experimental Biology and Medicine. 228 (5): 568–571. PMID12709588. doi:10.1177/15353702-0322805-29
Vítek L; Jirsa M; Brodanová M; et al. (2002). «Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels». Atherosclerosis. 160 (2): 449–56. PMID11849670. doi:10.1016/S0021-9150(01)00601-3